You are here

Structural Heart

 

Subclinical leaflet thrombosis occurred in 13.6 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and 3.8 percent of patients undergoing surgical aortic valve replacement (SAVR), according to an analysis of two registries.

The FDA approved the CoreValve Evolut PRO valve for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are at high or extreme risk for open heart surgery.

After two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), according to a randomized trial.

Courts in Germany and the United Kingdom have ruled that Edwards Lifesciences infringed on patents related to Boston Scientific’s transcatheter heart valves.

A new study from San Diego State University (SDSU) has revealed information on a heart protein that could play a critical role in the body’s ability to combat heart disease and recover from heart attack.

 

Recent Headlines

ACC.17: Subclinical leaflet thrombosis occurs more often in TAVR versus SAVR patients

Subclinical leaflet thrombosis occurred in 13.6 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and 3.8 percent of patients undergoing surgical aortic valve replacement (SAVR), according to an analysis of two registries.

FDA approves the CoreValve Evolut PRO TAVR valve for high or extreme risk patients

The FDA approved the CoreValve Evolut PRO valve for transcatheter aortic valve replacement (TAVR) in patients with severe, symptomatic aortic stenosis who are at high or extreme risk for open heart surgery.

ACC.17: SURTAVI trial finds TAVR, SAVR have similar all-cause mortality rates at 24 months

After two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), according to a randomized trial.

FDA expands approval of the Melody transcatheter pulmonary valve

The FDA approved the Melody transcatheter pulmonary valve for patients whose surgical bioprosthetic pulmonary heart valves failed.

Mayo Clinic, Children’s Hospital of Philadelphia collaborate on congenital heart disease program

The Mayo Clinic and the Children’s Hospital of Philadelphia are working together to delay and prevent heart failure from hypoplastic left heart syndrome (HLHS), a rare and complex form of congenital heart disease in children.

Courts in Germany, UK rule in Boston Scientific’s favor in TAVR patent cases

Courts in Germany and the United Kingdom have ruled that Edwards Lifesciences infringed on patents related to Boston Scientific’s transcatheter heart valves.

Natural protein could prevent damage from heart disease, heart attacks

A new study from San Diego State University (SDSU) has revealed information on a heart protein that could play a critical role in the body’s ability to combat heart disease and recover from heart attack.

Study finds Evolut R TAVR device is safe, effective at 30 days in high-risk patients

A prospective, single-arm, non-randomized study found that the CoreValve Evolut R device was safe and effective in the short-term in patients with severe aortic stenosis who underwent transcatheter aortic valve replacement (TAVR).

Children with congenital heart defects struggle with reading, math

Children with congenital heart defects were less likely to meet academic standards in reading or math at the end of third grade compared with children who did not have such defects, according to a retrospective cohort study.

Patients undergoing TAVR show significant health status improvement at 1 year

Patients undergoing transcatheter aortic valve replacement (TAVR) had major improvements in health status 30 days and one year after the procedure, according to an observational cohort study.

Pages